Press Releases

MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.

MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, to use the

Significant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applications MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality,

MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time. The call will be webcast live and may be accessed at

The companies will leverage high-throughput whole genome HiFi sequencing for advanced plant biotechnology, breeding and crop protection product development MENLO PARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing

Science magazine publication details how the human genome was finally completed with the help of PacBio long-read technology MENLO PARK, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, announced today

Company Announces New European Headquarters to Serve Growing Customer Demand in Europe, Middle East and Africa Region Also Announces First Commercial Services Provider in Europe MENLO PARK, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly

SickKids will use HiFi Sequencing to explore potential genetic causes of a range of medical and developmental conditions MENLO PARK, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PacBio , a leading provider of high-quality, highly accurate sequencing platforms, today announced it will be supporting The

MENLO PARK, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of

Genomics Industry Veteran to Oversee Development of Robust Computational Biology Program MENLO PARK, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, welcomes Michael Eberle, Ph.D., as Vice President of